Increased Platelet-monocyte Aggregation in Male Claudicants with the PlA1/A2 Polymorphism of Gp IIb/IIIa

European Journal of Vascular and Endovascular Surgery

Volumn 36, Issue 2, 2008, Pages 132-137

  McCaslin, J ^a   Ashour, H ^a   Bhattacharya, V ^a   Cleanthis, M ^b   Daly, A ^c   Stansby, G ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Aspirin; Genetic polymorphism; Peripheral arterial disease; Platelet

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR; LEUCINE; PROLINE;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CELL AGGREGATION; CLAUDICATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; MONOCYTE; MONOCYTE AGGREGATION; PHENOTYPE; PRIORITY JOURNAL; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

AGED; ASPIRIN; BLOOD PLATELETS; FEMALE; FLOW CYTOMETRY; GENE FREQUENCY; GENOTYPE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MONOCYTES; PERIPHERAL VASCULAR DISEASES; PHENOTYPE; PLATELET ADHESIVENESS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSPECTIVE STUDIES; SEX FACTORS;

EID: 46749156927     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2008.02.016     Document Type: Article

References (48)

1. Cooke G.E., Bray P.F., Hamlington J.D., Pham D.M., and Goldschmidt-Clermont P.J. PlA2 polymorphism and efficacy of aspirin. Lancet 351 9111 (1998) 1253
2. Szczeklik A., Undas A., Sanak M., Frolow M., and Wegrzyn W. Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol 110 4 (2000) 965-967
3. Undas A., Sanak M., Musial J., and Szczeklik A. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. [comment]. Lancet 353 9157 (1999) 982-983
4. Weiss E.J., Bray P.F., Tayback M., Schulman S.P., Kickler T.S., Becker L.C., et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. [see comment]. N Engl J Med 334 17 (1996) 1090-1094
5. Feng D., Lindpaintner K., Larson M.G., O'Donnell C.J., Lipinska I., Sutherland P.A., et al. Platelet glycoprotein IIIa Pl(a) polymorphism, fibrinogen, and platelet aggregability: the Framingham Heart Study. Circulation 104 2 (2001) 140-144
6. Faraday N., Martinez E.A., Scharpf R.B., Kasch-Semenza L., Dorman T., Pronovost P.J., et al. Platelet gene polymorphisms and cardiac risk assessment in vascular surgical patients. Anesthesiology 101 6 (2004) 1291-1297
7. Meiklejohn D.J., Urbaniak S.J., and Greaves M. Platelet glycoprotein IIIa polymorphism HPA 1b (PlA2): no association with platelet fibrinogen binding. Br J Haematol 105 3 (1999) 664-666
8. Smith F.B., Connor J.M., Lee A.J., Cooke A., Lowe G.D.O., Rumley A., et al. Relationship of the platelet glycoprotein PlA and fibrinogen T/G + 1689 polymorphisms with peripheral arterial disease and ischaemic heart disease. Thromb Res 112 4 (2003) 209-216
9. Li N., Goodall A.H., and Hjemdahl P. A sensitive flow cytometric assay for circulating platelet-leucocyte aggregates. Br J Haematol 99 4 (1997) 808-816
10. Feng D., Lindpaintner K., Larson M.G., Rao V.S., O'Donnell C.J., Lipinska I., et al. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 19 4 (1999) 1142-1147
11. Goodall A.H., Curzen N., Panesar M., Hurd C., Knight C.J., Ouwehand W.H., et al. Increased binding of fibrinogen to glycoprotein IIIa-proline33 (HPA-1b, PlA2, Zwb) positive platelets in patients with cardiovascular disease. [see comment]. Eur Heart J 20 10 (1999) 742-747
12. Michelson A.D., Furman M.I., Goldschmidt-Clermont P., Mascelli M.A., Hendrix C., Coleman L., et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. [see comment]. Circulation 101 9 (2000) 1013-1018
13. Lasne D., Krenn M., Pingault V., Arnaud E., Fiessinger J.N., Aiach M., et al. Interdonor variability of platelet response to thrombin receptor activation: influence of PlA2 polymorphism. Br J Haematol 99 4 (1997) 801-807
14. Bennett J.S., Catella-Lawson F., Rut A.R., Vilaire G., Qi W., Kapoor S.C., et al. Effect of the Pl(A2) alloantigen on the function of beta(3)-integrins in platelets. Blood 97 10 (2001) 3093-3099
15. Robless P.A., Tegos T.J., Okonko D., Mansfield A.O., Nicolaides A.N., Mikhailidis D.P., et al. Platelet activation during carotid endarterectomy and the antiplatelet effect of Dextran 40. Platelets 13 4 (2002) 231-239
16. Robless P.A., Okonko D., Lintott P., Mansfield A.O., Mikhailidis D.P., and Stansby G.P. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg 25 1 (2003) 16-22
17. Schmitz G., Rothe G., Ruf A., Barlage S., Tschope D., Clemetson K.J., et al. European working group on clinical cell analysis: consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 79 5 (1998) 885-896
18. Sorel N., Brabant S., Christiaens L., Brizard A., Mauco G., and Macchi L. A rapid and specific whole blood HPA-1 phenotyping by flow cytometry using two commercialized monoclonal antibodies directed against GP IIIa and GP IIb-IIIa complexes. Br J Haematol 124 2 (2004) 221-223
19. Mikkelsson J., Perola M., Laippala P., Penttila A., and Karhunen P.J. Glycoprotein IIIa Pl(A1/A2) polymorphism and sudden cardiac death. J Am Coll Cardiol 36 4 (2000) 1317-1323
20. Unkelbach K., Kalb R., Santoso S., Kroll H., Mueller-Eckhardt C., and Kiefel V. Genomic RFLP typing of human platelet alloantigens Zw(PlA), Ko, Bak and Br (HPA-1, 2, 3, 5). Br J Haematol 89 1 (1995) 169-176
21. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. [see comment]. J Am Coll Cardiol 41 6 (2003) 961-965
22. Jefferson B.K., Foster J.H., McCarthy J.J., Ginsburg G., Parker A., Kottke-Marchant K., et al. Aspirin resistance and a single gene. Am J Cardiol 95 6 (2005) 805-808
23. Lepantalo A., Mikkelson J., Resendiz J.C., Viiri L., Backman J.T., Kankuri E., et al. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 95 (2006) 253-259
24. Eikelboom J.W., and Hankey G.J. Aspirin resistance: a new independent predictor of vascular events?. J Am Coll Cardiol 41 6 (2003) 966-968
25. Boudoulas K.D., Cooke G.E., Roos C.M., Bray P.F., and Goldschmidt-Clermont P.J. The PlA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation. Arch Pathol Lab Med 125 1 (2001) 112-115
26. Boudoulas K.D., Montague C.R., Goldschmidt-Clermont P.J., and Cooke G.E. Estradiol increases platelet aggregation in Pl(A1/A1) individuals. Am Heart J 152 1 (2006) 136-139
27. Rinder C.S., Gaal D., Student L.A., and Smith B.R. Platelet-leukocyte activation and modulation of adhesion receptors in pediatric patients with congenital heart disease undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 107 1 (1994) 280-288
28. Serrano Jr. C.V., Ramires J.A., Venturinelli M., Arie S., D'Amico E., Zweier J.L., et al. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol 29 6 (1997) 1276-1283
29. Serrano Jr. C.V., Rocha Giraldez R., de Lara Fernandes J., Nicolau J.C., Zweier J.L., and Ramires J.A.F. Platelet and leukocyte adhesion and activation in unstable angina and post-PTCA. Int J Cardiol 99 3 (2005) 423-428
30. Mickelson J.K., Lakkis N.M., Villarreal-Levy G., Hughes B.J., and Smith C.W. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease?. J Am Coll Cardiol 28 2 (1996) 345-353
31. Htun P., Fateh-Moghadam S., Tomandl B., Handschu R., Klinger K., Stellos K., et al. Course of platelet activation and platelet-leukocyte interaction in cerebrovascular ischemia. Stroke 37 9 (2006) 2283-2287
32. Gawaz M., Reininger A., and Neumann F.J. Platelet function and platelet-leukocyte adhesion in symptomatic coronary heart disease. Effects of intravenous magnesium. Thromb Res 83 5 (1996) 341-349
33. May A.E., Neumann F.J., Gawaz M., Ott I., Walter H., and Schomig A. Reduction of monocyte-platelet interaction and monocyte activation in patients receiving antiplatelet therapy after coronary stent implantation. Eur Heart J 18 12 (1997) 1913-1920
34. Zimmerman G.A., Elstad M.R., Lorant D.E., McLntyre T.M., Prescott S.M., Topham M.K., et al. Platelet-activating factor (PAF): signalling and adhesion in cell-cell interactions. Adv Exp Med Biol 416 (1996) 297-304
35. Weyrich A.S., Elstad M.R., McEver R.P., McIntyre T.M., Moore K.L., Morrissey J.H., et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 97 6 (1996) 1525-1534
36. Furie B., and Furie B.C. The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand, PSGL-1. Thromb Haemost 74 1 (1995) 224-227
37. Spangenberg P., Redlich H., Bergmann I., Losche W., Gotzrath M., and Kehrel B. The platelet glycoprotein IIb/IIIa complex is involved in the adhesion of activated platelets to leukocytes. Thromb Haemost 70 3 (1993) 514-521
38. Sanderson H.M., Fox S.C., Robbins R.A., Losche W., Spangenberg P., and Heptinstall S. Role of GPIIb-IIIa in platelet-monocyte and platelet-neutrophil conjugate formation in whole blood. Platelets 9 3-4 (1998) 245-250
39. Neumann F.J., Zohlnhofer D., Fakhoury L., Ott I., Gawaz M., and Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol 34 5 (1999) 1420-1426
40. Michelson A.D., Barnard M.R., Krueger L.A., Valeri C.R., and Furman M.I. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 104 13 (2001) 1533-1537
41. Rosin C., Brunner M., Lehr S., Quehenberger P., and Panzer S. The formation of platelet-leukocyte aggregates varies during the menstrual cycle. Platelets 17 1 (2006) 61-66
42. Aldrighi J.M., Oliveira R.L.S., D'Amico E., Rocha T.R.F., Gebara O.E., Rosano G.M.C., et al. Platelet activation status decreases after menopause. Gynecol Endocrinol 20 5 (2005) 249-257
43. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 6921 (1994) 81-106
44. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - II: maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 308 6922 (1994) 159-168
45. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 308 6923 (1994) 235-246
46. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. [see comment]. Lancet 2 8607 (1988) 349-360
47. CAPRIE investigators. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE Trial). Am J Cardiol 90 7 (2002) 760-762
48. CURE Study Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502